Explore the words cloud of the PREFERABLE project. It provides you a very rough idea of what is the project "PREFERABLE" about.
The following table provides information about the project.
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
|Coordinator Country||Netherlands [NL]|
|Total cost||4˙121˙130 €|
|EC max contribution||3˙983˙347 € (97%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2019-01-01 to 2023-12-31|
Take a look of project's partnership.
|1||UNIVERSITAIR MEDISCH CENTRUM UTRECHT||NL (UTRECHT)||coordinator||1˙025˙436.00|
|2||JULIUS CLINICAL RESEARCH BV||NL (ZEIST)||participant||724˙040.00|
|3||KAROLINSKA INSTITUTET||SE (STOCKHOLM)||participant||406˙035.00|
|4||STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS||NL (AMSTERDAM)||participant||381˙770.00|
|5||NUROGAMES GMBH||DE (KOLN)||participant||336˙625.00|
|6||FUNDACION ONKOLOGIKOA FUNDAZIOA||ES (DONOSTIA SAN SEBASTIAN)||participant||262˙550.00|
|7||GDANSKI UNIWERSYTET MEDYCZNY||PL (GDANSK)||participant||260˙850.00|
|8||DEUTSCHE SPORTHOCHSCHULE KOLN||DE (KOLN)||participant||242˙025.00|
|9||DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG||DE (HEIDELBERG)||participant||235˙025.00|
|10||UNIVERSITATSKLINIKUM HEIDELBERG||DE (HEIDELBERG)||participant||77˙741.00|
|11||EUROPA DONNA THE EUROPEAN BREAST CANCER COALITION||IT (MILANO)||participant||31˙250.00|
|12||AUSTRALIAN CATHOLIC UNIVERSITY LIMITED||AU (NORTH SYDNEY)||participant||0.00|
Despite the tremendous improvement in early diagnosis and treatment of breast cancer, a large proportion (up to 40%) of patients with breast cancer will eventually develop metastases. Patients with metastatic breast cancer (MBC) have a median overall survival of 2-3 years, and a relative 5-year survival of 34%. Current advances in therapy have extended the life of those patients with MBC, however these patients still suffer (for longer periods) from deleterious side-effects (either related to the disease itself or to the treatment) such as fatigue, pain, nausea and vomiting, insomnia, dyspnoea, emotional, social and cognitive dysfunction. Among all these side-effects, fatigue is the most common and distressing treatment-related side-effect, as up to 90% of patients with MBC experience fatigue over the course of treatment. All these symptoms negatively affect patients’ QoL and thus an urgent solution is needed to help those with advanced breast cancer to “live well” for as long as possible. PREFERABLE’s vision is to improve the standard of care in MBC by improving the quality, effectiveness and cost-effectiveness for patients in a palliative setting using a non-pharmacological intervention combining supervised and unsupervised app-based exercise. Based on the results from a multinational randomised controlled phase 3 clinical trial (EFFECT trial; (cost)- effectiveness study), the different perspectives of patients with MBC on exercising (PERSPECTIVE study), and through mapping the differences in the European healthcare systems, the PREFERABLE project will generate solid and conclusive evidence of the beneficial effect of exercise on cancer-related side effects and patients’ quality of life in the palliative setting. By this, PREFERABLE will contribute towards reshaping medical practice and improving clinical guidelines and recommendations.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PREFERABLE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PREFERABLE" are provided by the European Opendata Portal: CORDIS opendata.
Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone MetastasisRead More
Collaboration for innovation: Establishment of a pan-nematode drug development platformRead More
Global Alliance for Chronic Diseases SecretariatRead More